ArticleScientific reports2025

Cost-effectiveness of benmelstobart and anlotinib plus chemotherapy as first-line therapy for extensive-stage small cell lung cancer in China.

Chunyan Yan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.